Women Speak Tasmania raised serious questions with the Tasmanian Government in May about clinical governance, evidence and safeguards in the provision of puberty suppression and gender-affirming hormones to patients under 18. Three months later, new developments have made those questions more urgent.
When governments are responsible for the care of children, waiting for greater certainty can be understandable. But what happens when the evidence remains contested, significant safety questions are unresolved, and the national review that is meant to address them will not deliver final guidelines until 2028? At what point does continued waiting become a failure to act?
What we asked
On 6 May 2026 we wrote to the Minister for Health, the Hon Bridget Archer MP. We asked about clinical governance, the quality of the evidence, informed consent, transparency, and the State’s duty of care to children and adolescents.
We pointed to the findings of the Cass Review, emerging concerns from Australian reviews, the limited evidence base for medical interventions in minors, and the absence of comprehensive public data on treatment and long-term outcomes. We asked whether Tasmania would consider:
- an independent clinical governance review of the Tasmanian Gender Service;
- interim precautionary measures, including a pause on new Stage 1 and Stage 2 initiations in the public system;
- mandatory, centralised data collection and public reporting;
- stronger monitoring of adverse events and long-term outcomes; and
- appropriate oversight of treatment in the private sector.
Our concern was straightforward: where evidence is uncertain and interventions may have lifelong consequences, clinical governance must be exceptionally robust.
The Minister’s response
On 11 June the Minister replied that the Tasmanian Government is committed to the health and wellbeing of children and young people. She stated that the Tasmanian Gender Service is a specialised service, that referrals come from medical practitioners with guardian consent, and that risks, benefits and outcomes are discussed by a multidisciplinary team. Critically, she advised that:
“the service is consistent with current Australian Standards”
and that Tasmania would closely monitor the NHMRC’s national review.
What has changed
On 15 August The Australian reported a significant development arising from legal proceedings in the United States. According to the report, lawyers for the World Professional Association for Transgender Health (WPATH) told a US court in its statements that:
“Standards of Care are opinions about what conclusions existing scientific research supports.”
The filing also described transgender healthcare as an area of “significant medical debate,” with WPATH acknowledging it is on one side of that debate.
This matters. WPATH guidance has been highly influential internationally. The Australian standards used for children have been closely modelled on WPATH guidance through AusPATH. If the Tasmanian Gender Service is considered consistent with current Australian standards, the Government now needs to explain what it makes of emerging questions about the evidentiary foundations of those standards.
Professional guidelines provide a framework for practice. They do not, by themselves, establish that every recommendation is supported by high-quality evidence. That distinction is especially important when treating children and adolescents with interventions that can have significant and potentially irreversible consequences.
The latest development challenge the idea that those recommendations can be treated as beyond legitimate scientific debate.
The problem with waiting until 2028
The NHMRC review is welcome. Interim findings on puberty blockers are expected late 2026; the full guidelines are not expected until 2028. A future review cannot undo a medical intervention that has already occurred. Children receiving treatment today cannot wait for certainty that may arrive years later.
This is why we raised the possibility of interim precautionary measures in May. We were not arguing that every clinical question must be resolved before any care can be offered. We were asking whether, in circumstances of significant uncertainty, governments should strengthen safeguards while the evidence is properly examined.
Vulnerability and Caution
These are not abstract questions. In a separate account published on 15 August, a mother writing as “Sarah B” described her teenage daughter’s serious psychological difficulties—including hallucinations, self-harm and anorexia—before the girl obtained testosterone online and used it for months without parental knowledge. The account illustrate why questions about vulnerable children, informed consent, access to powerful hormones, and long-term outcomes deserve careful attention.
Sarah B’s central point is simple and important: informed consent requires an honest discussion of what is known, what is uncertain, where the evidence is strong and where it is weak. A vulnerable young person should not have to carry the burden of resolving contested scientific questions. Parents should not be expected to accept that the existence of professional guidelines automatically means the underlying evidence is settled.
If the answers are uncertain, caution should come before confidence.
What Tasmania should do now
The circumstances have changed since June. The foundations of the model are under increasing international scrutiny. The evidence base remains contested. The national review is ongoing and the final guidelines are not expected until 2028.
Women Speak Tasmania therefore asks the Tasmanian Government to reconsider the questions we put in May. At a minimum, Tasmania should:
- Commission an independent clinical governance review of the Tasmanian Gender Service, covering referral pathways, assessment processes, informed-consent procedures, treatment criteria, multidisciplinary arrangements and follow-up.
- Implement transparent, centralised data collection on referrals, assessments, treatments, adverse events and long-term outcomes. Without meaningful data, governments cannot evaluate whether a model of care is achieving the outcomes claimed for it.
- Ensure genuine informed consent. Families must receive clear information about both potential benefits and the limitations and uncertainties in the evidence.
- Strengthen safeguarding so that assessment of gender distress takes full account of a child’s psychological health, developmental history and other vulnerabilities, with appropriate safeguards where significant mental-health difficulties are present.
- Consider interim safeguards while the NHMRC review proceeds. Waiting for a final report in 2028 does not remove the Government’s responsibility for children receiving treatment today.
The question that remains
Is Tasmania doing enough to protect vulnerable children while the evidence is being reviewed?
The appropriate response to uncertainty is not to pretend it does not exist. It is to investigate it, collect the data, listen to parents and clinicians who raise legitimate concerns, and scrutinise the evidence independently. Where children face potentially lifelong consequences, the precaution we would expect in any other area of paediatric medicine must apply.
Children should not have to wait for governments to achieve certainty before reasonable safeguards are strengthened.
Women Speak Tasmania will continue to examine the evidence and advocate for transparent, accountable and child-centred healthcare policy.